Regulations.gov document
Response Letter from FDA CDER to Boehringer Ingelheim Pharma GmbH & Co. KG, Hogan Lovells…
Other · FDA-2011-E-0117 · posted Dec 29, 2014
Key facts
| Document ID | FDA-2011-E-0117-0008 |
|---|---|
| Title | Response Letter from FDA CDER to Boehringer Ingelheim Pharma GmbH & Co. KG, Hogan Lovells US LLP |
| Document type | Other |
| Subtype | Answer |
| Agency | FDA |
| Docket | FDA-2011-E-0117 |
| Posted | Dec 29, 2014 |
| Comment period opens | Dec 29, 2014 |
At a glance
- 1–9 Public comments on this docket
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About Regulations.gov documents
Regulations.gov holds the rulemaking and other documents federal agencies post for public comment. Only agency documents are published here; public submissions are not.
Source: Regulations.gov (U.S. General Services Administration eRulemaking Program) · Source date: